Cambridge Clinical Mitochondrial Research Group
Current studies
CCMR Two
A phase IIa, randomised, double-blind, placebo-controlled trial of the ability of the combination of metformin and clemastine to promote remyelination in people with relapsing-remitting multiple sclerosis already on disease modifying therapy
Study Team: Nick Cunniffe, Chris McMurran, Will Brown, Alasdair Coles, Riddhima Gautam
ION-PROM
Development of a patient reported outcome measure (PROM) for patients with inherited optic neuropathy (ION) [ION-PROM]
Study Team: Benson Chen, Patrick Yu Wai Man
Collaborators: Stephanie Archer (Cambridge), Valerija Tadić (Greenwich), Mike Horton (Leeds), Tasanee Braithwaite (Kings), Konrad Pesudovs (Sydney), Robert Pitceathley (UCL)
ARMOUR One
An observation study Assessing Remyelinating Measures with the Objective of Understanding Repair in multiple sclerosis and in demyelinating conditions of the central nervous system.
Study Team: Gioia Riboni Verri, Jonathon Holland, Alasdair Coles, Nick Cunniffe, Riddhima Gautam
ORION
An observational Outcomes Research study in Inherited Optic Neuropathies to determine the natural history of inherited optic neuropathies and identify novel biomarkers of disease.
eyeHD
Assessing Huntington’s Disease patients for ophthalmological abnormalities as a measure of disease stage.
FALCON study
A prospective natural history study of patients with autosomal dominant optic atrophy.
Previous studies
- Alzheimer Biomarker Consortium – Down Syndrome (ABC-DS) Study: Observational study to identify biomarkers of Alzheimer’s disease in people with Down’s syndrome.
- SPRINGER: Studying progressive remyelination in nerves by grading electrophysiological recovery
- Study Team: Nick Cunniffe, Chris McMurran, Trisha Mukherjee, Will Brown, Alasdair Coles
- PROSPAX: Understanding the progression over time of hereditary spastic paraplegia (HSP), ataxia and related conditions.
Study Team: Benson Chen, Patrick Yu Wai Man